Advisors
Dr Stephen Cash
Dr Cash is currently CEO of NanoCentral. He started his career with ICI covering sales, marketing, logistics, strategic planning, and new business development. In 1992, Dr Cash led the first ICI business unit MBO, establishing Cleveland Chemicals Ltd, later sold to the Yule Catto group. Since then he has worked in new business development and technology scouting for Thomas Swan & Co Ltd, establishing world leading technologies in areas such as carbon nanotube and carbon nanofibre manufacture in addition to a number of start-up companies (Screen Technology plc, was floated on the AIM market). Dr Cash remains a non-executive director of four start-ups created during this time and sits on the advisory board of the Materials Science Department at the University of Cambridge.
Dr Jeffery Lindeman
Dr Lindeman is an esteemed Intellectual Property consultant and patent attourney at J. A. Lindeman LLC. A renowned thought leader in the field, Dr Lindeman is a world-leading expert in legal issues relating to pharmaceutical solid form intellectual property.
Dr Scott Childs
Dr Childs is a recognised leader in the field of pharmaceutical development and brings 15 years of experience in studying drug solid form from an academic and industrial perspective. Now an independent researcher, Dr. Childs continues to research and publish in this area. In addition to the development of high-throughput cocrystal screening methods, current research interests include formulation and bioavailability studies using rapidly dissolving cocrystals of low solubility drugs.